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SWI/SNF chromatin remodeling com-
plexes utilize ATP to alter histone-DNA
interactions and activate or repress the
expression of numerous eukaryotic
genes. In humans, SWI/SNF complexes
contain approximately 10 sub-
units, including either the SNF2
family ATPase BRM (Brahma) or
BRG1 (Brahma related gene 1).
The ability of these subunits to
bind to other known tumor sup-
pressors, the loss of expression of
these genes in some human
tumor cell lines, and the increased
cell proliferation and/or low level
of tumor formation in genetically
altered mice lacking these sub-
units has suggested a connection
between SWI/SNF chromatin
remodeling complexes and can-
cer. A third subunit, SNF5 (also
know as INI1 or BAF47), is a core
subunit of all human SWI/SNF
complexes. SNF5 physically inter-
acts with several tumor-related
proteins and is mutated in chil-
dren with malignant rhabdoid
tumors (MRT) (Versteege et al.,
1998). Subsequent analysis per-
formed by several groups has
documented germline mutations
of hSNF5, with deletion or muta-
tion of the remaining wild-type hSNF5
allele occurring in MRT of the kidney and
brain. In addition, biallelic hSNF5 muta-
tions have also been observed in spo-
radic renal rhabdoid tumors and in
choroid plexus carcinomas, meduloblas-
tomas, and central primitive neuroecto-
dermal tumors (reviewed in Roberts and
Orkin, 2004).
The ability of SNF5 to function as a
tumor suppressor has been confirmed in
studies utilizing Snf5-deficient mice.
Snf5 null mice die at the peri-implanta-
tion stage in early embryogenesis. Mice
haploinsufficient for Snf5 undergo nor-
mal development, but 5%–35% later pre-
sent with rhabdoid tumors and other
tumor types, many of which are highly
aggressive and metastatic (Roberts et
al., 2000, Klochendler-Yeivin et al., 2000,
Guidi et al., 2001). Where examined,
tumorigenesis correlates with loss or
inactivation of the remaining wild-type
Snf5 allele. More recently, Orkin and
coworkers generated both an inactivat-
ing-conditional Snf5 allele and a
reversibly inactivating-conditional Snf5
allele in mice (Roberts et al., 2002).
Inhibition of Snf5 expression in a variety
of adult tissues resulted in bone marrow
failure and rapid death, whereas spo-
radic inactivation of Snf5 in hematopoiet-
ic tissues and in other organs resulted in
rapid onset of lymphomas and rhabdoid
tumors. Collectively, these mouse stud-
ies demonstrate that Snf5 suppresses
tumor formation by some undetermined
mechanism yet is absolutely required for
the survival of nonmalignant cells.
Insight into the mechanism of Snf5-
mediated tumor suppression has been
provided by studies performed in cul-
tured MRT cells. Reintroduction of
hSNF5 into hSNF5-deficient human
MRT-derived cell lines induces flat
cell morphology, an accumulation
of cells in G1/G0, and, in some
cases, cell senescence or apopto-
sis (Ae et al., 2002, Versteege et
al., 2002).These effects appear to
be mediated through the
retinoblastoma (Rb) tumor sup-
pressor, since addition of Rb func-
tion is sufficient to restore G1
arrest to cells lacking Snf5 (Betz
et al., 2002). Phosphorylation of
Rb by cyclin-dependent kinases
promotes entry of the cells into S
phase by releasing Rb from E2F
transcription factors, and MRT
cells transduced with hSNF5
exhibit Rb hypophosphorylation
and decreased expression of E2F
target genes. Furthermore, chro-
matin immunoprecipitation exper-
iments have indicated that hSNF5
alters Rb activity by inhibiting the
expression of cyclin D1 (Zhang et
al., 2002) or by activating the tran-
scription of the p16Ink4a tumor sup-
pressor gene (Oruetxebarria et
al., 2004). Increased p16Ink4A (Ink4A =
inhibitor of kinase 4A) activity inhibits cell
cycle progression into S phase by pre-
venting cyclin D1-CDK4 kinase induced
phosphorylation of Rb, leaving the Rb
corepressor complexed with E2F tran-
scription factors (Figure 1).
The results suggest that hSNF5 sup-
presses tumor formation by regulating cell
proliferation via the Rb cell cycle check-
point. However, it is unclear whether the
antiproliferative effects of hSNF5 are sole-
ly responsible for preventing cancer. A
recent paper by the Verrijzer group
explores this question further (Vries et al.,
2005). In their study, the authors used an
inducible promoter system to re-express
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SNF5 is a core subunit of the SWI/SNF chromatin-remodeling complex. Mammalian SNF5 is essential for normal cell viabil-
ity, and loss or mutation of the human SNF gene is the molecular basis for familial malignant rhabdoid tumorigenesis.
Previous studies have suggested that SNF5 suppresses cancer by signaling through the p16Ink4a and retinoblastoma
tumor suppressors to negatively regulate cell cycle progression from G0/G1 into S phase. A recent paper in Genes &
Development (Vries et al., 2005) reports that human SNF5 also signals via the p16INK4a-Rb-E2F pathway to regulate chro-
mosomal stability, suggesting a new function for this chromatin remodeling protein in tumor suppression.
Figure 1. Modulation of the Rb tumor suppressor pathway by
hSNF5
By increasing expression of p16 and inhibiting expression of
cyclin D1, SNF5 promotes the inactivation of E2F transcrip-
tion factors by Rb, thereby negatively regulating cell growth
and maintaining numerical chromosomal stability. Tumor
suppressor proteins are shown in blue.
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into hSNF null MRT cells either wild-type
hSNF5 or mutant versions of hSNF5 that
contain single amino acid substitutions
previously identified in MRT samples.The
results indicate that tumor-associated,
mutant hSNF5 genes are capable of
reducing cell proliferation, though not as
well as wild-type hSNF5, suggesting that
failed growth arrest may not fully explain
the association of these hSNF5 mutations
with MRT. Multilobed nuclei were
observed in both hSNF5 null MRT cells
and non-MRT cells following induction of
the expression of one of the cancer-asso-
ciated hSNF5 genes. This altered nuclear
morphology was seen routinely in hSNF5
null MRT cells, but never in cells trans-
duced with wild-type hSNF5. This led the
authors to test whether expression of the
mutant hSNF5 promotes polyploidization.
Using multicolor pq-COBRA-FISH analy-
sis, it was determined that 10% of the
hSNF5 null MRT cells were near
tetraploid and 90% were numerically
diploid, albeit with more than half of the
cells bearing multiple chromosomal aber-
rations. Strikingly, induction of hSNF5
expression in these cells for 96 hr resulted
in a nearly 100% diploid population,
whereas induction of a mutant hSNF5 led
to centrosome and spindle amplifications
and exacerbated the polyploidization and
aneuploidization of the cells, suggesting a
role for hSNF5 in mitotic checkpoint con-
trol. Although several of the tested hSNF5
mutations further increased the chromo-
somal instability of hSNF5 null MRT cells,
not all cancer-associated hSNF5 muta-
tions had this effect, indicating the 
presence of both gain-of-function and
loss-of-function hSNF5 mutations in MRT.
In addition, the authors examined
the karyotypes of noncycling and cycling
hSNF5-expressing cells and found that
the noncycling cells displayed signifi-
cantly more chromosomal gains and
losses that the mitotic cells, suggesting
that the accumulation of diploid MRT
cells following reintroduction of hSNF5 is
due to the arrest or senescence of aneu-
ploid cells in the population. Whole-
genome expression profiling revealed
changes to many E2F targets, including
several genes known to be involved in
mitotic control and regulation of ploidy.To
test if the p16Ink4a-CDK4/cyclinD-Rb-
E2F pathway was also involved in
hSNF5-mediated regulation of ploidy, the
authors expressed a p16Ink4a-insensi-
tive CDK4 mutant in MRT cells and
determined that the high level of aneu-
ploidy and polyploidy in these trans-
duced cells could not be reversed by
induction of hSNF5 expression.
The results of this study define a new
critical function for hSNF5, thereby
expanding previous models of hSNF5-
mediated tumor suppression.The authors
propose that loss of hSNF5 in normal
cells results in reduced p16Ink4a levels
and increased phosphorylation of Rb (by
CDK4/cyclin D), leading to an increase in
E2F levels (Figure 1). Intriguingly, loss of
hSNF5 correlates with upregulation of
E2F target genes that have been linked to
increased cell proliferation and to mitotic
defects and aneuploidy. The ability of
hSNF5 to regulate cell proliferation and
chromosomal ploidy in MRT cells indi-
cates that loss of hSNF5 in cells can
induce both the growth advantage and the
chromosomal instability needed for tumor
induction and progression. This work and
previous studies reveal a convergence of
the hSNF5 and Rb tumor suppressor
pathways. What other mutations must
occur in order for primary cells undergo-
ing loss of SNF5 to retain viability and
become cancerous remains to be deter-
mined. Furthermore, it is unclear if this is
the only mechanistic pathway utilized by
hSNF5 to regulate neoplasia. As part of
the SWI/SNF chromatin remodeling com-
plex, hSNF5 presumably assists in regu-
lating the expression of many genes, and
the absolute requirement of hSnf5 for cell
viability and during early embryogenesis
indicates that hSNF5 is likely playing mul-
tiple roles in regulating normal cell growth.
Finally, it should be noted that there is
scant evidence that hSNF5 is regulating
tumorigenesis solely via the SWI/SNF
complex. Indeed, recent evidence sug-
gests that SWI/SNF complexes can func-
tion in the absence of hSNF5, suggesting
that hSNF5-mediated suppression of
MRT may not involve SWI/SNF (Doan et
al., 2004). Clearly, more work will be
needed to elucidate all of the functional
roles of hSNF5 in tumor suppression.
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